Istanbul – 07 May 2014 - Covidien plc has officially opened Covidien Center of Innovation Turkey (CCI Turkey), expanding its training and research capabilities in emerging markets. Located in Istanbul, The new center will have the capacity to train more than 5,000 health care professionals annually from within Turkey and the surrounding region.
CCI Turkey will focus on raising awareness of various disease states and providing opportunities for clinicians to see how Covidien’s solutions can help health care professionals treat these diseases. Top training priorities will include procedures and protocols to address vascular disease, metabolic disorders (obesity and Type II diabetes) and COPD (Chronic Obstructive Pulmonary Disease).
“This center is designed to enhance physician capabilities in a way that meets the unique needs of the local market, ultimately giving patients in Turkey greater access to advanced procedures and care,” said Mats Eklof, president, EMEA Emerging Markets, Covidien. “On top of that, our R&D engineers will observe, listen and work closely with health care professionals to uncover opportunities for locally tailored solutions that address unmet needs in Turkey and the broader emerging markets.”
CCI Turkey is Covidien’s fourth training center in an emerging market, with other centers located in Shanghai, China; Mumbai, India; and Osong, South Korea. The company also plans to open a center this year in São Paulo, Brazil.
Turkey is an important and growing market for Covidien, which has operated in the country since 2001. The company has approximately 200 employees in the country.
Covidien is a leading global healthcare products company. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries.
Source: Covidien plc